China SXT Pharmaceuticals Stock to Reverse Split on Tuesday, February 3rd (NASDAQ:SXTC)

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares are set to reverse split on the morning of Tuesday, February 3rd. The 1-50 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, February 2nd.

China SXT Pharmaceuticals Price Performance

NASDAQ:SXTC traded down $0.02 on Friday, reaching $0.03. The stock had a trading volume of 64,536,454 shares, compared to its average volume of 36,097,512. China SXT Pharmaceuticals has a 1-year low of $0.03 and a 1-year high of $7.84. The stock has a fifty day moving average price of $1.05 and a 200-day moving average price of $1.37.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its quarterly earnings results on Wednesday, December 31st. The company reported ($0.03) EPS for the quarter. The company had revenue of $0.31 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of China SXT Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, China SXT Pharmaceuticals presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

A hedge fund recently raised its stake in China SXT Pharmaceuticals stock. Virtu Financial LLC boosted its stake in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) by 107.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 28,983 shares of the company’s stock after buying an additional 15,013 shares during the period. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.